Gupta R C, Canerdy T D, Skaggs P, Stocker A, Zyrkowski G, Burke R, Wegford K, Goad J T, Rohde K, Barnett D, DeWees W, Bagchi M, Bagchi D
Toxicology Department, Murray State University, Murray/Hopkinsville, KY 42240, USA.
J Vet Pharmacol Ther. 2009 Dec;32(6):577-84. doi: 10.1111/j.1365-2885.2009.01079.x.
The present investigation evaluated arthritic pain in horses receiving daily placebo, undenatured type II collagen (UC-II) at 320, 480, or 640 mg (providing 80, 120, and 160 mg active UC-II, respectively), and glucosamine and chondroitin (5.4 and 1.8 g, respectively, bid for the first month, and thereafter once daily) for 150 days. Horses were evaluated for overall pain, pain upon limb manipulation, physical examination, and liver and kidney functions. Evaluation of overall pain was based upon a consistent observation of all subjects during a walk and a trot in the same pattern on the same surface. Pain upon limb manipulation was conducted after the walk and trot. It consisted of placing the affected joint in severe flexion for a period of 60 sec. The limb was then placed to the ground and the animal trotted off. The response to the flexion test was then noted with the first couple of strides the animal took. Flexion test was consistent with determining clinically the degree of osteoarthritis in a joint. Horses receiving placebo showed no change in arthritic condition, while those receiving 320 or 480 or 640 mg UC-II exhibited significant reduction in arthritic pain (P < 0.05). UC-II at 480 or 640 mg dose provided equal effects, and therefore, 480 mg dose was considered optimal. With this dose, reduction in overall pain was from 5.7 +/- 0.42 (100%) to 0.7 +/- 0.42 (12%); and in pain upon limb manipulation from 2.35 +/- 0.37 (100%) to 0.52 +/- 0.18 (22%). Although glucosamine and chondroitin treated group showed significant (P < 0.05) reduction in pain compared with pretreated values, the efficacy was less compared with that observed with UC-II. In fact, UC-II at 480 or 640 mg dose was found to be more effective than glucosamine and chondroitin in arthritic horses. Clinical condition (body weight, body temperature, respiration rate, and pulse rate), and liver (bilirubin, GGT, and ALP) and kidney (BUN and creatinine) functions remained unchanged, suggesting that these supplements were well tolerated.
本研究评估了每日接受安慰剂、320毫克、480毫克或640毫克未变性II型胶原蛋白(UC-II)(分别提供80毫克、120毫克和160毫克活性UC-II)以及葡萄糖胺和软骨素(第一个月分别为5.4克和1.8克,每日两次,此后每日一次)的马匹的关节炎疼痛,为期150天。对马匹进行了总体疼痛、肢体触诊时的疼痛、体格检查以及肝肾功能评估。总体疼痛评估基于在同一表面以相同模式对所有受试者进行行走和小跑期间的一致观察。行走和小跑后进行肢体触诊时的疼痛评估。方法是将受影响的关节极度屈曲60秒。然后将肢体放在地上,让动物小跑离开。接着记录动物最初几步对屈曲试验的反应。屈曲试验与临床确定关节骨关节炎的程度一致。接受安慰剂的马匹关节炎状况无变化,而接受320毫克、480毫克或640毫克UC-II的马匹关节炎疼痛显著减轻(P<0.05)。480毫克或640毫克剂量的UC-II效果相同,因此,480毫克剂量被认为是最佳剂量。采用该剂量时,总体疼痛从5.7±0.42(100%)降至0.7±0.42(12%);肢体触诊时的疼痛从2.35±0.37(100%)降至0.52±0.18(22%)。虽然葡萄糖胺和软骨素治疗组与治疗前相比疼痛显著减轻(P<0.05),但其疗效低于UC-II组。事实上,在患有关节炎的马匹中,480毫克或640毫克剂量的UC-II比葡萄糖胺和软骨素更有效。临床状况(体重、体温、呼吸频率和脉搏率)以及肝脏(胆红素、γ-谷氨酰转移酶和碱性磷酸酶)和肾脏(血尿素氮和肌酐)功能保持不变,表明这些补充剂耐受性良好。